Appeal type: Experimental/Investigational
Decision: Upheld

Diagnosis: Low Back Pain
Treatment: Intraosseous Basivertebral Ablation (code 64628)
The insurer denied: Intraosseous Basivertebral Ablation (code 64628)
The denial is overturned.

The patient is an adult male with history of chronic low back pain of more than seven years. The pain has affected his ADLs (activities of daily living) and functionality. The treating physician concluded that the pain is vertebrogenic and that he will benefit from Intracept intraosseous nerve ablation for the ablation of basivertebral nerves at L5 (lumbar five) and S1 (sacral one).
The patient's MRI (magnetic resonance imaging) of the lumbar spine showed Modic types 2 signal changes at L5/S1. The patient as failed conservative measures, including home exercise program, chiropractic manipulation, physical therapy, spinal injections, over the counter NSAIDs (non-steroidal anti-inflammatory drugs), etc. The health plan denied coverage of the requested Intracept procedure, citing lack of enough proof or 
not enough proof that it improves health, and they deemed it as investigational. The reason for the appeal is its relevance in treating vertebrogenic pain.

The health plan should cover the requested Intracept procedure.

The request is medically appropriate based on general standard of care for vertebrogenic pain. It also meets the following recommended requirements by RELIEVANT, the Intracept Medical device manufacturer, as per the FDA (United States Food and Drug Administration)-approved requirements and indication for which the device is approved (3):
* Intracept is medically indicated in patients who have:
* A history of low back pain of at least 6 months duration; and
* Failed to respond to at least 6 months of non-surgical management; and
* MRI (magnetic resonance imaging) demonstrated Modic Type 1 or Type 2 changes at one or more vertebrae from L3 to S1; and
* Activities of daily living that are limited by persistent low back pain; and all other reasonable sources of pain have been ruled out.
Per Khalil J, Smuck M, Koreckij T, et al, "The purpose of this RCT [randomized controlled trial] was to compare the effectiveness of intraosseous RF [radiofrequency] ablation of the BVN [basivertebral nerve] to standard care for the treatment of chronic LBP [low back pain] in a specific subgroup of patients suspected to have vertebrogenic related symptomatology." Their conclusion 
notes, "Minimally invasive RF [radiofrequency] ablation of the BVN [basivertebral nerve] led to significant improvement of pain and function at 3-months in patients with chronic vertebrogenic 
related LBP [low back pain]."
Per a study performed by Fischgrund JS, Rhyne A, Franke J, et al, "The purpose of the present study is to report the 2-year clinical outcomes for chronic low back pain (CLBP) patients treated with radiofrequency (RF) ablation of the basivertebral nerve (BVN) in a randomized controlled trial that previously reported 1-year follow up." The conclusions of this study are cited as, "Patients treated with RF [radiofrequency] ablation of the BVN [basivertebral nerve] for CLBP [chronic low back pain] exhibited sustained clinical benefits in ODI [Oswestry Disability Index] and VAS [Visual Analogue Scale] and maintained high responder rates at 2 years following treatment. Basivertebral 
nerve ablation appears to be a durable, minimally invasive treatment for the relief of CLBP [chronic low back pain]."
The patient in this case presents with a history of chronic low back pain of more than 12 months. He has tried and failed conservative measures, all treatment exceeding 12 months. The pain has affected his functionality. The magnetic resonance imaging (MRI) of the lumbar spine showed Modic type 2 changes at lumbar five/sacral one (L5/S1) vertebral body. Therefore, based on the submitted information, current peer-reviewed literature and the current standards of care, the requested Intracept Procedure would be considered medically appropriate in this case.